Inventor · disambiguated record
Guodong Chen
Also filed as: CHEN GUODONG
44 granted patents·19 pending applications·248 citations·filing 2001–2025
98Inventor score
Top patents by PatentIndex Score
63 records- 0198US9228016B2Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2015·Granted Jan 5, 2016·85 cites·19 claims
- 0297US10501550B2Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2016·Granted Dec 10, 2019·9 cites·58 claims
- 0397US10465010B2Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2017·Granted Nov 5, 2019·9 cites·15 claims
- 0497US9745379B2Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2015·Granted Aug 29, 2017·11 cites·58 claims
- 0597US9605080B2Antibodies against CD73BRISTOL MYERS SQUIBB CO·Filed 2016·Granted Mar 28, 2017·31 cites·30 claims
- 0696US10100129B2Antibodies against CD73 and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2015·Granted Oct 16, 2018·24 cites·35 claims
- 0795US11767364B2TL1A antibodies and methods of treatmentBRISTOL MYERS SQUIBB CO·Filed 2021·Granted Sep 26, 2023·4 cites·9 claims
- 0895US11008395B2Antibodies against IL-7R alpha subunit and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2020·Granted May 18, 2021·5 cites·25 claims
- 0994US12312403B2Antibodies against TIM3 and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2023·Granted May 27, 2025·1 cites·17 claims
- 1094US11084881B2Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2019·Granted Aug 10, 2021·3 cites·19 claims
- 1194US10077306B2Antibodies against TIM3 and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2017·Granted Sep 18, 2018·7 cites·22 claims
- 1293US11213586B2Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR)BRISTOL MYERS SQUIBB CO·Filed 2016·Granted Jan 4, 2022·5 cites·14 claims
- 1393US10533052B2Antibodies against TIM3 and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2018·Granted Jan 14, 2020·4 cites·30 claims
- 1493US8945553B2Bispecific antibodies to IL-23 and IL-17A/FBRISTOL MYERS SQUIBB CO·Filed 2013·Granted Feb 3, 2015·16 cites·12 claims
- 1592US10690674B2Anti-GITR antibodies for cancer diagnosticsBRISTOL MYERS SQUIBB CO·Filed 2016·Granted Jun 23, 2020·5 cites·27 claims
- 1691US10968279B2TL1A antibodies and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2017·Granted Apr 6, 2021·6 cites·12 claims
- 1790US12077584B2Methods of treating HLA-E-expressing cancers by administering antibodies which bind human natural killer cell inhibitory receptor group 2A (NKG2A)BRISTOL MYERS SQUIBB CO·Filed 2022·Granted Sep 3, 2024·1 cites·76 claims
- 1890US10167343B2Antibodies against CD73BRISTOL MYERS SQUIBB CO·Filed 2017·Granted Jan 1, 2019·3 cites·34 claims
- 1988US11919954B2Anti-TREM-1 antibodies and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2021·Granted Mar 5, 2024·1 cites·28 claims
- 2088US11524992B2Glypican-3-binding fibronectin based scaffold moleculesBRISTOL MYERS SQUIBB CO·Filed 2020·Granted Dec 13, 2022·2 cites·12 claims
- 2188US11274150B2Anti-human natural killer cell inhibitory receptor group 2A protein (NKG2A) antibodiesBRISTOL MYERS SQUIBB CO·Filed 2019·Granted Mar 15, 2022·2 cites·113 claims
- 2288US2024158524A1Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2023·Application pending·0 cites
- 2387US2024209083A1Antibodies against tim3 and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2023·Application pending·0 cites
- 2486US11591392B2Antibodies against TIM3 and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2019·Granted Feb 28, 2023·1 cites·19 claims
- 2584US11408889B2Anti-GITR antibodies for cancer diagnosticsBRISTOL MYERS SQUIBB CO·Filed 2020·Granted Aug 9, 2022·1 cites·20 claims
- 2684US11155618B2Anti-TREM-1 antibodies and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2019·Granted Oct 26, 2021·1 cites·35 claims
- 2783US11242393B2Antibodies against MICA and/or MICB and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2019·Granted Feb 8, 2022·3 cites·19 claims
- 2883US2025101100A1Anti-nkg2a antibodies and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2024·Application pending·0 cites
- 2981US10584160B2Glypican-3-binding fibronectin based scaffold moleculesBRISTOL MYERS SQUIBB CO·Filed 2016·Granted Mar 10, 2020·3 cites·22 claims
- 3081US2024228615A1Anti-trem-1 antibodies and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2024·Application pending·0 cites
- 3180US2023051701A1Antibodies against cd73 and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2022·Application pending·0 cites
- 3279US2023050665A1Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2021·Application pending·0 cites
- 3378US12492238B2Glypican-3-binding fibronectin based scaffold moleculesBRISTOL MYERS SQUIBB CO·Filed 2022·Granted Dec 9, 2025·0 cites·6 claims
- 3478US11981734B2Nucleic acid molecules encoding antibodies which bind natural killer cell inhibitory receptor group 2A protein (NKG2A)BRISTOL MYERS SQUIBB CO·Filed 2022·Granted May 14, 2024·0 cites·163 claims
- 3578US2024174749A1Methods of treating cancer with antibodies against tim3BRISTOL MYERS SQUIBB CO·Filed 2023·Application pending·0 cites
- 3678US2024417478A1Antibodies against il-7r alpha subunit and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2024·Application pending·0 cites
- 3777US12173069B2Antibodies binding to vista at acidic pHFIVE PRIME THERAPEUTICS INC·Filed 2019·Granted Dec 24, 2024·1 cites·28 claims
- 3877US11802162B2Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2019·Granted Oct 31, 2023·0 cites·25 claims
- 3976US12435136B2Antibodies binding to ILT4FIVE PRIME THERAPEUTICS INC·Filed 2022·Granted Oct 7, 2025·0 cites·42 claims
- 4076US11708405B2IP-10 antibodies and their usesBRISTOL MYERS SQUIBB CO·Filed 2019·Granted Jul 25, 2023·1 cites·21 claims
- 4176US2025326841A1Antibodies against tim3 and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2025·Application pending·0 cites
- 4276US2025115664A1Antibodies against tim3 and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2024·Application pending·0 cites
- 4375US10556948B2IP-10 antibodies and their usesBRISTOL MYERS SQUIBB CO·Filed 2016·Granted Feb 11, 2020·2 cites·19 claims
- 4475US9783606B2Polynucleotides encoding IL-17/IL-23 bispecific, IL-17A/F and IL-23p19 antibodiesBRISTOL MYERS SQUIBB CO·Filed 2014·Granted Oct 10, 2017·1 cites·71 claims
- 4575US2025129166A1Antibodies Binding to Vista at Acidic pHFIVE PRIME THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 4674US11952420B2Nucleic acids encoding anti-TREM-1 antibodiesBRISTOL MYERS SQUIBB CO·Filed 2021·Granted Apr 9, 2024·0 cites·25 claims
- 4772US11352440B2Antibodies against CD73 and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2018·Granted Jun 7, 2022·0 cites·18 claims
- 4871US11919962B2Antibodies against IL-7R alpha subunit and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2021·Granted Mar 5, 2024·0 cites·29 claims
- 4971US2022175921A1Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2021·Application pending·0 cites
- 5068US2025197494A1Methods of treating cancer with antibodies against tim3BRISTOL MYERS SQUIBB CO·Filed 2025·Application pending·0 cites
Showing the top 50 of 63 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Guodong Chen files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →